14401-73-1

Basic information

• Product Name: 3,5-Dibromoacetophenone
• Synonyms: 3',5'-DIBROMOACETOPHENONE;3,5-DIBROMOACETOPHENONE;3,5-DIBROMOACETOPHENONE 99%MIN
• CAS NO: 14401-73-1
• Molecular Formula: C₈H₆Br₂O
• Molecular Weight: 277.94
• Product Categories: Aromatic Acetophenones & Derivatives (substituted);Adehydes, Acetals & Ketones;Bromine Compounds;organic chemicals and derivatives/others;OLED
• Mol File: 14401-73-1.mol

Chemical Properties

• Melting Point: 68°C
• Boiling Point: 318°C at 760 mmHg
• Flash Point: 118.5°C
• Appearance: /
• Density: 1.7855 (rough estimate)
• Vapor Pressure: 0.000372mmHg at 25°C
• Refractive Index: 1.5560 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3,5-Dibromoacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dibromoacetophenone(14401-73-1)
• EPA Substance Registry System: 3,5-Dibromoacetophenone(14401-73-1)

Safety Data

• Hazardous Substances Data: 14401-73-1(Hazardous Substances Data)

Usage

Uses

3',5'-Dibromoacetophenone is a useful research chemical.

InChI:InChI=1/C8H6Br2O/c1-5(11)6-2-7(9)4-8(10)3-6/h2-4H,1H3

Upstream product

• 127-19-5 N,N-dimethyl acetamide 
• 626-39-1 1,3,5-trisbromobenzene 
• 141-78-6 ethyl acetate 
• 75-36-5 acetyl chloride 
• 13445-89-1 1-(2-amino-3,5-dibromophenyl)ethanone 
• 7697-37-2 nitric acid 
• 1080603-07-1 3,5-dibromo-N-methoxy-N-methyl-benzamide 
• 75-16-1 methylmagnesium bromide 
• 676-58-4 methylmagnesium chloride 
• 99-92-3 p-aminobenzophenone 
• 59785-43-2 3,5-dibromo-1-ethylbenzene 
• 618-58-6 3,5-dibromobenzoic acid 
• 917-54-4 methyllithium 
• 22589-50-0 4-amino-3,5-dibromo-acetophenone 

Downstream Products

• 535992-33-7 1-(3,5-dibromo-2-nitro-phenyl)-ethanone 
• 29102-67-8 1,3,5-tris(3′,5′-dibromophenyl)benzene 
• 37960-84-2 [3,5-D₂]benzoic acid 
• 116772-87-3 C₈H₄⁽²⁾H₆O 
• 81500-93-8 2-(3,5-dibromophenyl)-2-methyl-(1,3)-dioxolane 
• 618-58-6 3,5-dibromobenzoic acid 
• 335274-54-9 3,5-bis(4-thiobnzylphenyloxy)-1-acetophenone 
• 956462-45-6 2-(3,5-dibromophenyl)-4-phenylquinoline 
• 832080-38-3 C₆H₃(C₆H₃(C₅H₄N)2)3 
• 335274-57-2 3,5-bis(4-chlorosulfonylphenyloxy)-1-acetophenone 
• 81500-98-3 3,5-bis(trimethylsilyl)acetophenone 
• 81500-95-0 2-<3,5-bis(trimethylsilyl)phenyl>-2-methyl-(1,3)-dioxolane 
• 644982-21-8 [1-(3,5-dibromo-phenyl)-ethyl]-methylamine 
• 909111-24-6 1,3-dibromo-5-(1-phenylvinyl)benzene 

Relevant articles and documents

A palladium(II)-clipped aromatic sandwich

A filling that makes the sandwich: Large aromatic molecules are sandwiched by two π-conjugated ligands (L) that are joined together by six {(en)Pd} 2+ units (M; en = 1,2-ethanediamine; see picture; guest red, {(en)Pd}2+ yellow, ligand blue). This host has an M6L 2 composition and is distorted by the concave shape of the ligand. Without a guest, it releases the distortion by forming the dimeric M 12L4 in a reversible fashion.

High-spin polyphenoxyls attached to star-shaped poly(phenylenevinylene)s

Star-shaped poly(1,2-phenylenevinylene)s 4-substituted with multiple pendant phenoxyls (2 and 3) were synthesized by polymerizing 2-bromo-4-(acetoxyphenyl)styrene in the presence of 1,3,5-triiodobenzene or 1,3,5-tris(3′,5′-diiodophenyl)benzene as the core via a simple one-pot Heck reaction and subsequent hydrolysis, phenolate formation, and heterogeneous oxidation. ESR spectra indicated a delocalized spin distribution into the core parts of the star-shaped molecules. The polyradicals, 2 and 3, were in a high-spin state at low temperature, and the ferromagnetic behavior was enhanced for the polyradical with a higher molecular weight. Although an average S of 3 remained at 3/2 to 4/2, the polyradical 2 even with a spin concentration of 0.8 spin/unit revealed an average S of 7/2 to 8/2. The 1,3,5-benzene core acted as an effective magnetic coupler to align the spins of the pendant phenoxyls through the star-shaped π-conjugated backbone.

PHENANTHROLINE-TRIAZINE COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING THE SAME

The present invention relates to a phenanthroline-triazine compound, capable of improving driving voltage and efficiency, and to an organic light emitting device including the same. The phenanthroline-triazine compound is represented by formula 1 or 2. In the chemical formula 1 or 2, X1, X2, X3 and X4 are independently carbon or nitrogen.COPYRIGHT KIPO 2019

Direct Transformation of Ethylarenes into Primary Aromatic Amides with N -Bromosuccinimide and I2-Aqueous NH3

A variety of ethylarenes were converted into the corresponding primary aromatic amides in good yields via treatment with N-bromosuccinimide in the presence of a catalytic amount of 2,2′-azobis(isobutyronitrile) in a mixture of ethyl acetate and water, acetonitrile and water, or chloroform and water, followed by reaction with molecular iodine and aq NH3 in one pot. It was found that aryl α-bromomethyl ketones and/or aryl methyl ketones were formed at the first reaction step and their iodoform-type reaction occurred at the second reaction step to provide primary aromatic amides. The present reaction is a useful and practical transition-metal-free method for the preparation of primary aromatic amides from ethylarenes. (Chemical Equation Presented).

A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex - Medicinal chemistry consequences of a TKs analysis

VEGFR2 is an important mediator of angiogenesis and influences fate of some cancer stem cells. Here we analysed all 34 structures of VEGFR2 TK available from PDB database. From them a complex PDB: 1Y6A has an exceptional AAZ ligand bound to TK in form of two conformers (U- and S-shaped). This observation inspired us to develop three chimeric bispyridyl VEGFR2 inhibitors by combining structural features of both AAZ conformers and/or their relative ligand AAX (PDB: 1Y6B). Our most interesting inhibitor 22SYM has an enzymatic VEGFR2 TK activity (IC50: 15.1 nM) comparable or better to the active compounds from clinical drugs Nexavar and Sutent. 22SYM inhibits growth, migration and tube formation of endothelial cells (EC) and selectively induces EC apoptosis. 22SYM also inhibits in vivo angiogenesis in Zebrafish embryo assay. Additionally to the above results, we proved here that tyrosine kinases in an inactive form possessing Type I inhibitors can adopt both a closed or an opened conformation of kinase A-loop independently on their DFG-out arrangement. We proposed here that an activity of certain Type I inhibitors (e.g. 22SYM-like) in complex with DFG-out TK can be negatively influenced by collisions with a dynamically moving TK A-loop.

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.